FDA has approved Zepbound for this, in the words of each label below. SURMOUNT-OSA (Tirzepatide): At 52 weeks, breathing interruptions (AHI) fell by 25.3 an hour on tirzepatide against 5.3 on placebo in people not using CPAP, and by 29.3 against 5.5 in people using it. ClinicalTrials.gov lists 13 trials of these medicines on it: 3 with posted results and 2 recruiting now.
Read from the registry and PubMed every day. The newest update here is Nov 2, 2026.
The approved use, word for word from each current label.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Tirzepatide · 469 people · Better than the comparison · Placebo-controlled randomized trial
At 52 weeks, breathing interruptions (AHI) fell by 25.3 an hour on tirzepatide against 5.3 on placebo in people not using CPAP, and by 29.3 against 5.5 in people using it.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Liraglutide | 3 | 2 | 0 |
| MariTide | 2 | 0 | 0 |
| Retatrutide | 2 | 0 | 0 |
| Semaglutide | 2 | 0 | 1 |
| Tirzepatide | 2 | 1 | 0 |
| Mazdutide | 1 | 0 | 1 |
| Orforglipron | 1 | 0 | 0 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| SURMOUNT-OSAObstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | Tirzepatide | Phase 3 | 469 | Change From Baseline in Apnea-Hypopnea Index (AHI) (events per hour), Baseline, Week 52. Tirzepatide MTD_GPI1: -25.25; Placebo_GPI1: -5.25; Tirzepatide MTD_GPI2: -29.27; Placebo_GPI2: -5.51. |
| NCT01557166Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea | Liraglutide | Phase 3 | 359 | Change From Baseline in Apnoea-hypopnoea Index (AHI) (events/hour), Week 0, Week 32. Liraglutide 3.0 mg: -12.22; Placebo: -6.08. |
| NCT01832532A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks | Liraglutide | Phase 1/2 | 34 | Change in Apnea Hypopnea Index (AHI) From Baseline (apnea / hypopnea events per hour sleep), Baseline and 4 weeks. Treatment Group- Liraglutide: 38.2; Control Group: 34. |
The registry page names each site and who can enroll. Ask your clinician before joining one.
| Trial | Medicine | Phase | Expected to finish |
|---|---|---|---|
| A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | Mazdutide | Phase 3 | Jun 11, 2027 |
| Impact GLP-1 Agonists Following Bariatric | Semaglutide | Phase 4 | Jul 2030 |
Meta-analysis · Sleep Breath · Oct 6, 2026 · Carvalhal G et al.
Meta-analysis · Front Endocrinol (Lausanne) · Aug 17, 2026 · Zheng J et al.
Meta-analysis · Nutr Rev · Jun 1, 2026 · Xu S et al. · cited by 6
Meta-analysis · Sleep Breath · Apr 24, 2026 · Dandamudi M et al. · cited by 1
Randomized trial · Clin Obes · Apr 1, 2026 · Wolsing SK et al.
Meta-analysis · Diabetes Obes Metab · Feb 23, 2026 · Chiappa GR et al.
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Written from each source's own record as it changes. Every change on GLPcompare
SURMOUNT-OSA (Tirzepatide, 469 people): At 52 weeks, breathing interruptions (AHI) fell by 25.3 an hour on tirzepatide against 5.3 on placebo in people not using CPAP, and by 29.3 against 5.5 in people using it.
Yes: Zepbound. Zepbound's label: to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Plans decide, and they usually tie coverage to a medicine's approved uses, so Zepbound is the place to start. Ask your plan whether it covers the medicine for this diagnosis and whether it needs prior authorization.
Liraglutide, with 3 registered trials on it, then MariTide with 2. More trials do not mean better results: read what each posted.
2 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.